News Agency
The Times

Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes

  • Written by PR Newswire
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes

Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026

LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology,...

Read more: Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk...

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion